COS Collagen Solutions Plc

TIDMCOS

RNS Number : 5426C

Collagen Solutions PLC

20 October 2020

Collagen Solutions plc

(the "Company")

Allotment of shares to employee benefit trust and Norgine

Statement of Total Voting Rights

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that:

-- on 19 October 2020 it allotted 18,625,000 new ordinary shares of GBP0.01 each in the Company ("New Ordinary Shares") to the trustee of the Collagen Solutions plc Employee Benefit Trust to facilitate the satisfaction of certain option exercises; and

-- on 20 October 2020 it allotted a further 2,325,764 new ordinary shares of GBP0.01 each in the Company (the "Further New Ordinary Shares") to Norgine Ventures Fund I S.C.A. SICAR ("Norgine") in satisfaction of the exercise of the warrants granted to Norgine pursuant to a warrant instrument issued in 2017, as subsequently adjusted under the terms of that instrument.

Both the above allotments relate to the satisfaction of proposals made by Rosen's Diversified, Inc. ("RDI") under Rule 15 of the Takeover Code in connection with its recommended cash offer (the "Offer") to acquire the entire issued and to be issued ordinary share capital of the Company not already owned by RDI. As stated in the announcement by RDI this morning, the Offer has been declared unconditional in all respects.

It is anticipated that the New Ordinary Shares and the Further New Ordinary Shares (which will rank pari passu in all respects with the existing ordinary shares of the Company) will be admitted to trading on AIM on or around 21 October 2020 ("Admission"). Following Admission, the Company's issued share capital will comprise 467,829,674 ordinary shares with voting rights and that figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company does not hold any shares in treasury.

For further information please contact:

 
Collagen Solutions Plc                                Contact via Walbrook 
Jamal Rushdy, Chief Executive Officer 
Hilary Spence, Chief Financial Officer 
 
Cenkos Securities plc (Nominated Adviser and Broker) 
Giles Balleny                                         Tel: 0207 397 8900 
Max Gould 
 
Walbrook PR                                           Tel: 020 7933 8780 or collagen@walbrookpr.com 
Anna Dunphy                                           Mob: 07876 741 001 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKKCBNKBDBFKD

(END) Dow Jones Newswires

October 20, 2020 02:03 ET (06:03 GMT)

Collagen Solutions (LSE:COS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Collagen Solutions (LSE:COS)
Gráfica de Acción Histórica
De May 2023 a May 2024